Scilex (SCLX) announced that it will be filing today of a Supplemental New Drug Application, SNDA, with the FDA for ELYXYB in acute pain ...
Merck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral HIF-2α inhibitor, Welireg (belzutifan), for a new indication. The sNDA is ...
Hosted on MSN2mon
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseThe sNDA has been accepted for review under the ... with two doses per year. Per the agreement, Alnylam has granted Novartis exclusive and worldwide rights to manufacture and commercialize RNAi ...
Holding announced that the U.S. FDA has acknowledged the submission of our Supplemental New Drug Application, SNDA, for ELYXYB in ...
Hosted on MSN26d
Sonida Senior Living Expands Portfolio and Extends LoansAdditionally, the company extended the maturity dates of its Fannie Mae loan agreements to 2029 ... $435.6M For a thorough assessment of SNDA stock, go to TipRanks’ Stock Analysis page.
At Sonida Senior Living, a filing with the SEC revealed that on Friday, Michael Simanovsky bought 42,111 shares of SNDA, at a cost of $21.32 each, for a total investment of $897,835. So far ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback